Plain-English translation of NCT05394714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called Magicell-NK, which uses your own immune cells to help prevent colon cancer from returning after surgery. Researchers will give you infusions of these cells—starting at different dose levels—to find out which dose is safest and works best. This is one of the first studies of this treatment in people, so the main goal is to make sure it's safe.
Even after successful surgery to remove early-stage colon cancer, there is still a risk the cancer could come back. This medication is designed to boost your body's natural immune system to help prevent that recurrence, offering a potential new option for patients who don't need traditional chemotherapy.
You likely qualify if…
You likely don't qualify if…
You will receive six infusions of the treatment over time at a hospital or clinic in Taiwan. Before you start, doctors will collect some of your immune cells, grow and activate them in the lab, and then infuse them back into your body. You'll have blood tests and check-ups to monitor how you're doing and watch for any side effects. The entire study will take several months, and researchers will follow your health closely to determine if this dose is safe.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
Taiwan